Trump strips job protections from NIH leadership

Good morning, healthcare professional.

The Trump administration is dismantling job protections for senior NIH officials and grants staff, a move that threatens the stability of the nation's premier biomedical research institution. Meanwhile, HHS authorizes experimental Ebola therapy even as NIH funding cuts weaken the infectious disease infrastructure designed to respond to such outbreaks. The Supreme Court delivered a unanimous decision favoring generic drugmakers in a landmark skinny labeling case, and ADC Therapeutics faces a major setback after patient deaths in a Phase 3 trial.

These developments signal profound shifts in federal research governance, pandemic preparedness, and drug development that will reverberate across the healthcare ecosystem for years to come.

In today's healthcare digest:

• NIH leadership faces removal of civil service protections under new Trump administration policy
• Experimental Ebola treatment authorized as research network crumbles from funding cuts
• ADC Therapeutics shares plummet following patient deaths in blood cancer drug trial
• Supreme Court rules unanimously for Hikma in skinny labeling dispute with Amarin

Trump Administration Strips Job Protections from NIH Officials

The Trump administration is removing job protections from senior NIH officials and grants staff, converting positions to at-will employment status. This represents a significant shift in federal research governance that could impact the agency's scientific independence and operational stability.

Unpacked:

• The policy targets high-level NIH leadership and grants administration staff who oversee billions in research funding.
• This move comes amid broader controversies surrounding RFK Jr.'s leadership at HHS and ongoing agency restructuring efforts.
• The change raises concerns about politicization of science and potential disruption to grant review processes affecting thousands of researchers.

Ebola Treatment Access Granted as Research Infrastructure Weakens

HHS confirmed that Americans with high-risk Ebola exposures will have access to experimental therapy MBP-134, particularly relevant given ongoing Kenya-related exposure concerns. However, NIH funding cuts have significantly weakened the infectious disease research network designed to respond to outbreaks.

Unpacked:

• The experimental therapy authorization provides a treatment option for individuals with documented high-risk Ebola exposures from Kenya.
• NIH budget reductions have dismantled key components of the infectious disease clinical research infrastructure built after previous outbreaks.
• The juxtaposition highlights a troubling pattern of authorizing emergency responses while simultaneously degrading preparedness capacity.

ADC Therapeutics Shares Sink on Phase 3 Trial Deaths

ADC Therapeutics' stock plummeted after the company reported patient deaths in a Phase 3 trial of Zynlonta, their antibody-drug conjugate for blood cancer. The safety concerns represent a major setback for the ADC specialist.

Unpacked:

• The deaths occurred during late-stage testing of Zynlonta, raising questions about the drug's risk-benefit profile in competitive oncology markets.
• ADC Therapeutics specializes in antibody-drug conjugates, making this safety signal particularly concerning for the company's core platform.
• The market reaction reflects investor concerns about potential regulatory delays and the drug's commercial viability.

Supreme Court Rules Unanimously for Generic Drugmaker in Skinny Label Case

The Supreme Court issued a unanimous decision favoring Hikma in its skinny labeling case against Amarin, clarifying when generic manufacturers can exclude certain uses from their labels. The ruling has significant implications for generic drug competition and pricing.

Unpacked:

• Skinny labeling allows generics to omit patented uses from their labels, potentially enabling earlier market entry without patent infringement.
• The unanimous decision provides clear legal guidance that could accelerate generic competition across multiple drug categories.
• The ruling affects patent strategy, drug pricing dynamics, and access to affordable medications throughout the pharmaceutical industry.

The Shortlist

• Legend Biotech shares surged on early data for an 'in vivo' CAR-T therapy for lymphoma, representing a potential advance in cell therapy delivery.

• Alnylam inked an AI partnership with Inceptive potentially worth $2 billion to develop foundation models for RNAi therapeutics.

• Lilly and Boehringer Ingelheim plan to slash at least $1 billion each from planned investments in Germany, citing regulatory challenges.

• Otsuka's kidney drug Voyxact slowed loss of function in late-stage trials, though results fell short of analyst expectations.

• Axsome successfully fended off generic competition to narcolepsy medication Sunosi through 2040 following patent settlements.